EGFR and non-small cell lung carcinoma: In 2016, the first ctDNA-based diagnostic test (cobas1 EGFR Mutation Test v2; Roche Diagnostics) was approved by the U.S. Food and Drug Administration (FDA), used to guide the application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors on the basis of specific EGFR-sensitizing mutations in patients with NSCLC [77,78].